Navigation Links
Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Date:8/4/2008

PALO ALTO, Calif., Aug. 4 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it has appointed Kurt Jarnagin, Ph.D., as its Vice President of Biological Research.

"We are pleased to welcome Kurt to the company," said Jacob Plattner, Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. "Kurt is a noted expert in the field of small molecule drugs involved in inflammation and his expertise will enrich our team as we continue to expand our pipeline fed by our boron chemistry platform."

Previously, Dr. Jarnagin was with Iconix Pharmaceuticals, Inc., serving as Vice President of Biology and Chemogenomics and Vice President of New Technology and Translational Medicine from 1998 to 2007. Dr. Jarnagin also held research leadership roles at Roche Pharmaceuticals (Palo Alto) from 1994 to 1998 and at Syntex Research, a specialty pharmaceutical company acquired by Roche, from 1986 to 1994.

At Iconix he directed the development of the DrugMatrix and ToxFX products -- tools and decision-making resources that aid scientists in the selection and prioritization of novel drugs. At Roche and Syntex he focused on drug discovery, targeting receptors and enzymes involved in inflammation, arthritis and asthma. Dr. Jarnagin was awarded the Fry-E. Werele International Kinin Chemistry Prize for work in the bradykinin field. He is the author of numerous peer-reviewed scientific papers and has several granted patents.

Dr. Jarnagin carried out highly cited studies of the insulin receptor at the Hormone Research Institute of the University of California, San Francisco. He received his Ph.D. in Biochemistry from the University of Wisconsin, Madison, and holds a B.S. in Biochemistry from North Carolina State University in Raleigh.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Anacor Files Registration Statement for Initial Public Offering
4. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
7. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
8. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
9. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
10. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
11. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci, in response ... customers three new solutions for measurements where traditional cuvette applications are not convenient. ... has an oddly-shaped sample that would not fit into a typical cuvette inside ...
(Date:1/12/2017)... , ... January 12, 2017 , ... Each year, Crain’s ... Index – a process that evaluates the patent estate of a company, its impact ... , a biomedical firm leading the way in technologies that transform energy sources such ...
(Date:1/12/2017)... , ... January 12, 2017 , ... Huffman Engineering, ... Stephen Beck, who will work in the company’s Lincoln office as a chemical engineer. ... to design control systems for customers in the life science manufacturing and water/wastewater industries. ...
(Date:1/12/2017)... January 12, 2017 The Energy ... biggest facility for producing mycorrhizae. The Centre for Mycorrhizal ... potential of mycorrhizae and developed a technology that eventually ... ... The TERI facility has a production ...
Breaking Biology Technology:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, co-founder ... Foundation Venture Capital Group, Inc., has been named to the elite ... Johnson, 27,  was one of 600 people in 20 fields nationwide ... four percent of the 15,000 applicants were selected. ... He is currently a PhD candidate ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):